AR036856A2 - Clorhidrato de paroxetina anhidro, y procedimiento para su preparacion - Google Patents

Clorhidrato de paroxetina anhidro, y procedimiento para su preparacion

Info

Publication number
AR036856A2
AR036856A2 ARP020103931A ARP020103931A AR036856A2 AR 036856 A2 AR036856 A2 AR 036856A2 AR P020103931 A ARP020103931 A AR P020103931A AR P020103931 A ARP020103931 A AR P020103931A AR 036856 A2 AR036856 A2 AR 036856A2
Authority
AR
Argentina
Prior art keywords
characteristic peaks
paroxetine hydrochloride
hydrochloride anhydrous
shows
theta
Prior art date
Application number
ARP020103931A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR036856(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9502297.6A external-priority patent/GB9502297D0/en
Priority claimed from GBGB9503112.6A external-priority patent/GB9503112D0/en
Priority claimed from GBGB9509807.5A external-priority patent/GB9509807D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AR036856A2 publication Critical patent/AR036856A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formas B, C y D de anhidro de clorhidrato de paroxetina que pueden ser utilizadas para tratar y prevenir desórdenes médicos, tales como depresión, desorden compulsivo obsesivo y pánico. El anhidro de clorhidrato de paroxetina en Forma B tiene un punto de fusión de alrededor de 138°C; bandas significativas IR a alrededor de 538, 574, 614, 675, 722, 762, 782, 815, 833, 884, 925, 938, 970, 986, 1006, 1039, 1069, 1094, 1114, 1142, 1182, 1230, 1274, 1304, 1488, 1510, 1574, 1604, 1631 cm-1; la endoterma de DSC, medida a 10°C por minuto muestra un máximo a aproximadamente 137°C en ambos un bol abierto y un bol cerrado; muestra también un difractograma de rayos X que incluye picos característicos a 5,7, 11,3, 12,4, 14,3 grados 2 theta y un espectro RMN de estado sólido que incluye los picos característicos a 154,6, 148,3, 150,1, 141,7, 142,7, 139,0 ppm. El anhidro de clorhidrato de paroxetina en Forma C tiene un punto de fusión de alrededor de 164°C, bandas significativas IR a alrededor de 540, 574, 615, 674, 720, 760, 779, 802, 829, 840, 886, 935, 965, 984, 1007, 1034, 1092, 1109, 1139, 1183, 1218, 1240, 1263, 1280, 1507, 1540, 1558, 1598, 1652 cm-1; la endoterma de DSC, medida a 10°C por minuto muestra un máximo a aproximadamente 161°C en ambos un bol abierto y un bol cerrado; muestra también un difractograma de rayos X que incluye picos característicos a 10,1, 12,1, 13,1, 14,3 grados 2 theta y un espectro RMN de estado sólido que incluye los picos característicos a 154,0, 148,5, 143,03, 140,4 ppm. El anhidro de clorhidrato de paroxetina en Forma D existe como un sólido semi-cristalino con un punto de fusión de alrededor de 125°C con características físicas similares a cuando es preparado a partir de un solvato precursor de tolueno, teniendo dicho solvato precursor de tolueno bandas significativas IR a alrededor de 1631, 1603, 1555, 1513, 1503, 1489, 1340, 1275, 1240, 1221, 1185, 1168, 1140, 1113, 1101, 1076, 1037, 1007, 986, 968, 935, 924, 885, 841, 818, 783, 760, 742, 720, 698, 672, 612, 572, 537 y 465 cm-1; y picos característicos de difracción de rayos X a 7,2, 9,3, 12,7, y 14,3 grados 2 theta. Se describe un procedimiento de preparación de anhidro de clorhidrato de paroxetina.
ARP020103931A 1995-02-06 2002-10-18 Clorhidrato de paroxetina anhidro, y procedimiento para su preparacion AR036856A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9502297.6A GB9502297D0 (en) 1995-02-06 1995-02-06 Novel compound
GBGB9503112.6A GB9503112D0 (en) 1995-02-17 1995-02-17 Novel compound
GBGB9509807.5A GB9509807D0 (en) 1995-05-15 1995-05-15 Novel compounds

Publications (1)

Publication Number Publication Date
AR036856A2 true AR036856A2 (es) 2004-10-06

Family

ID=27267578

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP960101230A AR001982A1 (es) 1995-02-06 1996-02-01 Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
ARP020103931A AR036856A2 (es) 1995-02-06 2002-10-18 Clorhidrato de paroxetina anhidro, y procedimiento para su preparacion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP960101230A AR001982A1 (es) 1995-02-06 1996-02-01 Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion

Country Status (47)

Country Link
EP (3) EP0808314B1 (es)
JP (2) JP2915338B2 (es)
KR (1) KR100289885B1 (es)
CN (3) CN1090187C (es)
AR (2) AR001982A1 (es)
AT (1) AT407528B (es)
AU (2) AU701518C (es)
BE (1) BE1009112A3 (es)
BG (1) BG62967B1 (es)
BR (1) BR9600534A (es)
CA (4) CA2210023C (es)
CH (3) CH688353A5 (es)
CZ (1) CZ297171B6 (es)
DE (3) DE19603797C2 (es)
DK (2) DK11996A (es)
DZ (1) DZ1989A1 (es)
ES (1) ES2114471B1 (es)
FI (3) FI111544B (es)
FR (1) FR2730232B1 (es)
GR (1) GR1002466B (es)
HK (1) HK59397A (es)
HU (1) HUP9600255A1 (es)
IE (1) IE80500B1 (es)
IL (1) IL117035A (es)
IT (1) IT1289532B1 (es)
LU (1) LU88711A1 (es)
LV (1) LV11618B (es)
MA (1) MA23802A1 (es)
MC (1) MC2411A1 (es)
MX (1) MX9600484A (es)
MY (1) MY132529A (es)
NL (1) NL1002248C2 (es)
NO (3) NO301009B1 (es)
NZ (1) NZ280943A (es)
OA (1) OA10261A (es)
PL (1) PL189247B1 (es)
PT (1) PT101827B (es)
RO (1) RO112426B1 (es)
RU (1) RU2125052C1 (es)
SE (1) SE521084C2 (es)
SG (1) SG43787A1 (es)
SI (2) SI21923B (es)
SK (1) SK283608B6 (es)
TR (1) TR199600096A2 (es)
TW (1) TW503238B (es)
UA (1) UA49796C2 (es)
WO (1) WO1996024595A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3882224B2 (ja) 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP1384720A1 (en) * 1996-06-13 2004-01-28 SUMIKA FINE CHEMICALS Co., Ltd. Process for drying paroxetine hydrochloride
JP2000514653A (ja) * 1996-07-15 2000-11-07 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 立体特異的分割のためのエステラーゼのスクリーニングおよびその使用
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
CA2193939C (en) * 1996-12-24 2002-02-12 K.S. Keshava Murthy Useful form of anhydrous paroxetine hydrochloride
ES2155995T3 (es) * 1997-06-10 2001-06-01 Synthon Bv Compuestos de 4-fenilpiperidina.
EP0903345B1 (de) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
GB9726907D0 (en) * 1997-12-19 1998-02-18 Smithkline Beecham Plc Novel compounds
SK13622000A3 (sk) * 1998-03-16 2001-03-12 Smithkline Beecham Plc Kryštalická forma paroxetínu, farmaceutický prostriedok a použitie
AU2003200534B2 (en) * 1998-03-24 2004-12-02 Smithkline Beecham Plc Paroxetine compositions
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
GB9806312D0 (en) * 1998-03-24 1998-05-20 Smithkline Beecham Plc Novel formulations
JP3796351B2 (ja) 1998-04-13 2006-07-12 住友化学株式会社 パロキセチン塩酸塩無水和物の乾燥方法
GB9812941D0 (en) * 1998-06-16 1998-08-12 Smithkline Beecham Plc Method of treatment
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2138937B1 (es) 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
ID27914A (id) * 1998-08-07 2001-05-03 Smithkline Beecham Plc Proses untuk penyiapan bentuk anhidrat paroksetina hidroklorida bukan kristal
GB9824298D0 (en) * 1998-11-05 1998-12-30 Smithkline Beecham Plc Novel process
GB9826175D0 (en) * 1998-11-28 1999-01-20 Smithkline Beecham Plc Novel process
GB9826176D0 (en) * 1998-11-28 1999-01-20 Smithkline Beecham Plc Novel process
GB9826178D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
DE69913377T2 (de) * 1998-11-30 2004-12-30 Smithkline Beecham P.L.C., Brentford Gemischte Paroxetin-Propan-2-ol-Solvate
GB9826171D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel compounds
GB9826180D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826242D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9828767D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
ATE311883T1 (de) * 1999-03-12 2005-12-15 Aesica Pharmaceuticals Ltd Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
GB9914583D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
GB9914585D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
GB9919001D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel process
GB9923446D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
GB9923445D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
GB9923439D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
HU226912B1 (en) * 2000-04-07 2010-03-01 Richter Gedeon Nyrt New paroxetin salt and medicament containing it
AU2001286232A1 (en) * 2000-09-14 2002-03-26 Asahi Glass Company, Limited Process for producing paroxetine salt containing substantially no organic solvent
AU2002259114A1 (en) * 2002-02-22 2003-09-09 Teva Pharmaceutical Industries Ltd. Preparation of paroxetine involving novel intermediates
WO2007062147A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Crystal forms of cinacalcet hci and processes for their preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
DE3688827T2 (de) * 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
EP0558679A1 (en) * 1990-11-24 1993-09-08 BEECHAM GROUP plc Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
PT101827B (pt) 1997-08-29
NO20015070L (no) 1996-08-07
NO970939D0 (no) 1997-02-28
ATA21096A (de) 2000-08-15
SE9600406D0 (sv) 1996-02-05
SI21923B (sl) 2006-12-31
MX198371B (es) 2000-08-29
LU88711A1 (fr) 1996-08-23
BG100333A (bg) 1996-08-30
HU9600255D0 (en) 1996-03-28
SE9600406L (sv) 1996-08-07
PL189247B1 (pl) 2005-07-29
DE69631298T2 (de) 2004-11-18
SK283608B6 (sk) 2003-10-07
FI20030370A (fi) 2003-03-12
NL1002248C2 (nl) 1996-09-11
IE80500B1 (en) 1998-08-12
CZ32096A3 (en) 1996-08-14
EP1378508A1 (en) 2004-01-07
FI111544B (fi) 2003-08-15
SG43787A1 (en) 1997-11-14
CA2211522A1 (en) 1996-08-07
DK200100223A (es) 2001-02-12
AU4332896A (en) 1996-08-15
CN1216055C (zh) 2005-08-24
SI9600036A (en) 1996-10-31
ES2114471B1 (es) 1999-08-16
RU2125052C1 (ru) 1999-01-20
BG62967B1 (bg) 2000-12-29
CA2210023A1 (en) 1996-08-07
NO301009B3 (es) 2003-01-06
CA2210023C (en) 1999-02-09
TR199600096A2 (tr) 1996-08-21
CA2168829C (en) 1997-12-16
IL117035A (en) 2000-02-29
RO112426B1 (ro) 1997-09-30
OA10261A (en) 1997-09-19
CN1289496C (zh) 2006-12-13
FI960519A (fi) 1996-08-07
CA2210022C (en) 2005-09-13
NL1002248A1 (nl) 1996-08-06
CH689229A5 (de) 1998-12-31
NO960472L (no) 1996-08-07
JP2915338B2 (ja) 1999-07-05
MX9600484A (es) 1997-01-31
FR2730232A1 (fr) 1996-08-09
MC2411A1 (fr) 1996-12-02
EP1136490B1 (en) 2004-01-07
EP0808314B1 (en) 2002-06-12
ES2114471A1 (es) 1998-05-16
EP0808314A1 (en) 1997-11-26
CA2168829A1 (en) 1996-08-07
HUP9600255A1 (en) 1997-03-28
DE69621777D1 (de) 2002-07-18
FI960519A0 (fi) 1996-02-05
NO301009B1 (no) 1997-09-01
BR9600534A (pt) 1997-05-13
DE19603797A1 (de) 1996-08-14
CN1310180A (zh) 2001-08-29
MY132529A (en) 2007-10-31
LV11618B (en) 1997-04-20
NZ280943A (en) 1997-01-29
FI20030162A (fi) 2003-02-03
AU701518B2 (en) 1999-01-28
CH688353A5 (de) 1997-08-15
SI9600036B (sl) 2006-12-31
NO960472D0 (no) 1996-02-05
ITMI960203A1 (it) 1997-08-05
CA2211522C (en) 1999-12-07
DE19603797C2 (de) 1998-11-12
IT1289532B1 (it) 1998-10-15
PT101827A (pt) 1996-09-30
MA23802A1 (fr) 1996-10-01
AT407528B (de) 2001-04-25
GR1002466B (el) 1996-11-06
NO970939L (no) 1996-08-07
NO311519B1 (no) 2001-12-03
CA2210022A1 (en) 1996-08-07
JPH08245620A (ja) 1996-09-24
CN1143643A (zh) 1997-02-26
DE69631298D1 (de) 2004-02-12
AU701518C (en) 2006-12-07
CH689804A5 (de) 1999-11-30
NO20015070D0 (no) 2001-10-18
AU4786496A (en) 1996-08-27
DE69621777T2 (de) 2003-01-02
SE521084C2 (sv) 2003-09-30
UA49796C2 (uk) 2002-10-15
DK11996A (da) 1996-08-07
DZ1989A1 (fr) 2002-10-15
HK59397A (en) 1997-05-16
AR001982A1 (es) 1998-01-07
SK14396A3 (en) 1996-11-06
WO1996024595A1 (en) 1996-08-15
FR2730232B1 (fr) 1997-08-01
IE960104A1 (en) 1996-08-07
CN1090187C (zh) 2002-09-04
TW503238B (en) 2002-09-21
JPH11228571A (ja) 1999-08-24
CZ297171B6 (cs) 2006-09-13
IL117035A0 (en) 1996-09-12
PL312646A1 (en) 1996-08-19
KR100289885B1 (ko) 2001-05-15
KR960031409A (ko) 1996-09-17
EP1136490A1 (en) 2001-09-26
SI21923A (sl) 2006-06-30
LV11618A (lv) 1996-12-20
CN1636993A (zh) 2005-07-13
BE1009112A3 (fr) 1996-11-05
ITMI960203A0 (es) 1996-02-05

Similar Documents

Publication Publication Date Title
AR036856A2 (es) Clorhidrato de paroxetina anhidro, y procedimiento para su preparacion
TW200628152A (en) Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorsers
PA8493701A1 (es) Compuestos para tratar la obesidad
WO2002074758A3 (en) Novel amines as histamine-3 receptor ligands and their therapeutic applications
MXPA01007968A (es) Compuestos derivados del felbamato.
DE60024588D1 (de) Substituierte porphyrine und deren therapeutische verwendungen
WO2003089434A3 (en) IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF
EP1759701A3 (en) Buproprion Metabolites and Methods of Their Synthesis and Use.
ES2117090T3 (es) Procedimiento para obtener formas granulares de aditivos para polimeros organicos.
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
DE69414554D1 (de) Heterocyclische verbindungen und ihre herstellung und verwendung
UY28815A1 (es) Agentes terapéuticos
CA2353133A1 (en) Treatment of disorders secondary to organic impairments
ATE475640T1 (de) Antagonisten des opioidrezeptors
GB9923077D0 (en) Sapogenin derivatives and their use
MX9306215A (es) Composicion novedosa para terapia peroral de un deterioro de la cognicion y un proceso para la fabricacion de la misma.
SE8503207D0 (sv) Pharmacologically active substituted benzamides
RU93051352A (ru) Замещенные производные циклогексана, способ их получения и применение соединений для лечения заболеваний
ES2084831T3 (es) Nuevo procedimiento para preparar formoterol y compuestos relacionados.
SE8808452A (sv) Pharmacologically active substituted benzamides
TW200607802A (en) 3-piperidinylisochroman-5-ols as dopamine agonists
DE60016181D1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
PT693070E (pt) Pirido(2,3-b)(1,4)benzodiazepinonas como ligando do receptor m2 para o tratamento de desordens neurologicas
WO2003082216A3 (en) Neuroprotectant methods, compositions, and screening methods thereof
WO2000047547A3 (en) Cycloalkyl amine compounds and uses thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure